Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2018 - 2026)

Allogene Therapeutics has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $396.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 22.05% year-over-year to $396.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (down 24.88% YoY) and the FY2025 annual result came in at $415.9 million, down 24.2% from the prior year.
• Liabilities and Shareholders Equity slipped to $396.0 million in Q1 2026 per ALLO's latest filing, from $415.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $978.1 million in Q1 2022 and troughed at $396.0 million in Q1 2026.
• A 5-year average of $654.7 million and a median of $642.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 13.37% in 2025, down 27.25% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $821.6 million in 2022, then dropped by 21.76% to $642.8 million in 2023, then decreased by 14.64% to $548.7 million in 2024, then declined by 24.2% to $415.9 million in 2025, then decreased by 4.8% to $396.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $396.0 million, $415.9 million, and $439.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.